Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Impact BioMedical, Inc. (IBO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/19/2025: IBO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 5 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/19/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.09M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.36 - 6.17 | Updated Date 06/28/2025 |
52 Weeks Range 0.36 - 6.17 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.07 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -7.06% | Return on Equity (TTM) -147.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 16971229 | Price to Sales(TTM) - |
Enterprise Value 16971229 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 4.72 | Shares Outstanding 12085400 | Shares Floating 11638131 |
Shares Outstanding 12085400 | Shares Floating 11638131 | ||
Percent Insiders 39.26 | Percent Institutions 3.19 |
Upturn AI SWOT
Impact BioMedical, Inc.
Company Overview
History and Background
Impact BioMedical, Inc. is a biopharmaceutical company focused on the development of therapeutics for infectious diseases and cancer. The company was founded in 2009. Its history includes a focus on developing novel antiviral and anticancer therapies, leveraging its proprietary technologies. More details can be found on SEC filings and company presentations.
Core Business Areas
- Anti-Infectives: Development of antiviral and antibacterial therapies to combat infectious diseases.
- Oncology: Development of anticancer therapeutics, including targeted therapies and immunotherapies.
Leadership and Structure
Impact BioMedical's leadership team consists of executives with experience in pharmaceutical development and commercialization. The organizational structure includes research, development, and corporate management divisions. Information available on their official website and SEC filings.
Top Products and Market Share
Key Offerings
- Equivir: Equivir is a broad-spectrum antiviral drug candidate. Specific market share data is not publicly available. Competitors include Gilead Sciences (GILD) and ViiV Healthcare.
- Ampligen: Ampligen is an immunotherapeutic drug candidate. Specific market share data is not publicly available. Competitors include companies developing similar immunotherapies, such as Merck (MRK) and Bristol-Myers Squibb (BMY).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. Demand is driven by unmet medical needs and aging populations.
Positioning
Impact BioMedical is positioned as a developer of novel therapies for infectious diseases and cancer, focusing on addressing unmet medical needs. Their competitive advantage lies in their proprietary technologies and unique drug candidates.
Total Addressable Market (TAM)
The global market for antiviral and anticancer drugs is estimated to be in the hundreds of billions of dollars. Impact BioMedical is positioned to capture a portion of this TAM through successful development and commercialization of its drug candidates.
Upturn SWOT Analysis
Strengths
- Proprietary technologies
- Novel drug candidates
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- High R&D risk
- Dependence on regulatory approvals
- Lack of commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies
- Accelerated regulatory pathways
Threats
- Competition from established pharmaceutical companies
- Patent challenges
- Clinical trial failures
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- GILD
- MRK
- BMY
- ABBV
Competitive Landscape
Impact BioMedical faces significant competition from larger, more established pharmaceutical companies. Its success depends on differentiating its drug candidates and securing strategic partnerships. Currently, they have limited or no market share compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in drug development and securing funding.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals for its drug candidates. Analyst estimates are not readily available.
Recent Initiatives: Recent initiatives include advancing clinical trials, seeking partnerships, and raising capital.
Summary
Impact BioMedical is a high-risk, high-reward biopharmaceutical company focused on developing novel therapies. Its strengths lie in its proprietary technologies and experienced management, but it faces challenges in securing funding and navigating regulatory hurdles. Positive clinical trial results are crucial for future success, and they will need to compete against companies with well established commercial networks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice. Financial data is estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Impact BioMedical, Inc.
Exchange NYSE MKT | Headquaters Houston, TX, United States | ||
IPO Launch date 2024-09-16 | Chairman & CEO Mr. Frank D. Heuszel Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.impactbiomedinc.com |
Full time employees 2 | Website https://www.impactbiomedinc.com | ||
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.